Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [PMID: 36483819 DOI: 10.12998/wjcc.v10.i33.12164]
Corresponding Author of This Article
Wei-Xiang Zhong, MA, Attending Doctor, Surgeon, Department of Thoracic Surgery, First Affiliated Hospital of Gannan Medical University, No. 128 Jinling West Road, Ganzhou 341000, Jiangxi Province, China. bronco067@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 26, 2022; 10(33): 12164-12174 Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12164
Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study
Wei-Xiang Zhong, Xi-Feng Wei
Wei-Xiang Zhong, Department of Thoracic Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, Jiangxi Province, China
Wei-Xiang Zhong, First Clinical Medical College, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Xi-Feng Wei, Department of Outpatient, Ganzhou Maternity and Child Health Hospital, Ganzhou 341000, Jiangxi Province, China
Author contributions: Zhong WX contributed to conception and design, data analysis and interpretation; Zhong WX and Wei XF collected and assembled the data, wrote the manuscript, and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Scientific Research Ethics Committee of the First Affiliated Hospital of Gannan Medical University (Approval No. LLSC-2021081601).
Informed consent statement: Patients were not required to give informed consent to the study, because the data used in this study were all anonymous, which were not involved in the patients’ privacy information, they were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at bronco067@126.com. The data used in this study were all anonymous, which were not involved in the patients’ privacy information, they were obtained after each patient agreed to treatment by written consent.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Xiang Zhong, MA, Attending Doctor, Surgeon, Department of Thoracic Surgery, First Affiliated Hospital of Gannan Medical University, No. 128 Jinling West Road, Ganzhou 341000, Jiangxi Province, China. bronco067@126.com
Received: August 7, 2022 Peer-review started: August 7, 2022 First decision: September 25, 2022 Revised: October 4, 2022 Accepted: October 24, 2022 Article in press: October 24, 2022 Published online: November 26, 2022 Processing time: 107 Days and 21.1 Hours
Core Tip
Core Tip: This study retrospectively analyzed the clinicopathological features of patients with co-mutations of EGFR and ALK genes in lung adenocarcinoma, and collected follow-up data of these patients, especially focusing on the tyrosine kinase inhibitors (TKIs) selected and its therapeutic effect in the real world from a single institute experience. The results showed that the positive rate of lung adenocarcinoma patients with co-mutations of EGFR and ALK genes, which were more common in women, non-smoking and stage IV patients with bone metastasis, was relatively high in Gannan region, which may be related to regional heterogeneity. EGFR-TKIs were their preferred drugs for targeted therapy in these patients, but the therapeutic effect is not good. EGFR/ALK dual-TKIs may be more effective targeted drugs.
